Video
Dr. Andreadis on CAR T-Cell Therapy for Pediatric ALL
Author(s):
Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the role of chimeric antigen receptor (CAR) T-cell therapy for pediatric patients with acute lymphocytic leukemia (ALL).
Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the role of chimeric antigen receptor (CAR) T-cell therapy for pediatric patients with acute lymphoblastic leukemia (ALL).
According to Andreadis, pediatric ALL is largely curable with available treatments. However, there is a subset of patients who do not do well with frontline therapy. Those patietns are now seeing responses with CAR T-cell therapy.
There are still problems with the longevity of response, explains Andreadis. It is not clear which patients will benefit from subsequent stem cell transplant versus being monitored once they respond to CAR T-cell therapy.
